References
- Terasaki P I. Humoral theory of transplantation. Am J Transplant 2003; 3: 665–673
- Gollackner B, Goh S K, Qawi I, Buhler L, Knosalla C, Daniel S, et al. Acute vascular rejection of xenografts: roles of natural and elicited xenoreactive antibodies in activation of vascular endothelial cells and induction of procoagulant activity. Transplantation 2004; 77: 1735–1741
- Salat C, Holler E, Kolb H J, Pihusch R, Reinhardt B, Hiller E. Endothelial cell markers in bone marrow transplant recipients with and without acute graft-versus-host disease. Bone Marrow Transplant 1997; 19: 909–914
- Nurnberger W, Michelmann I, Burdach S, Gobel U. Endothelial dysfunction after bone marrow transplantation: increase of soluble thrombomodulin and PAI-1 in patients with multiple transplant-related complications. Ann Hematol 1998; 76: 61–65
- Zeigler Z R, Rosenfeld C S, Andrews D F, III, Nemunaitis J, Raymond J M, Shadduck R K, et al. Plasma von Willebrand Factor Antigen (vWF:AG) and thrombomodulin levels (TM) in adult thrombotic thrombocytopenic purpura/hemolytic uremic syndromes (TTP/HUS) and bone marrow transplant-associated thrombotic microangiopathy (BMT-TM). Am J Hematol 1996; 53: 213–220
- Biedermann B C, Sahner S, Gregor M, Tsakiris D A, Jeanneret C, Pober J S, et al. Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease. Lancet 2002; 359: 2078–2083
- Mohty M, Kuentz M, Michallet M, Bourhis J H, Milpied N, Sutton L, et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation: long-term results of a randomized study. The Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC). Blood 2002; 100: 3128–3134
- Rocha V, Labopin M, Sanz G, Arcese W, Schwerdtfeger R, Bosi A, et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukaemia. N Engl J Med 2004; 351: 2276–2285
- Ishii H, Uchiyama H, Kazama M. Soluble thrombomodulin antigen in conditioned medium is increased by damage of endothelial cells. Thromb Haemost 1991; 65: 6118–6125
- Pearson J D. Markers of endothelial perturbation and damage. Br J Rheumatol 1993; 32: 651–652
- Testa S, Manna A, Porcellini A, Maffi F, Morstabilini G, Denti N, et al. Increased plasma level of vascular endothelial glycoprotein thrombomodulin as an early indicator of endothelial damage in bone marrow transplantation. Bone Marrow Transplant 1996; 18: 383–388
- Elliott M A, Nichols Jr WL, Plumhoff E A, Ansell S M, Dispenzieri A, Gastineau D A, et al. Post-transplantation thrombotic thrombocytopenic purpura: a single-center experience and a contemporary review. Mayo Clin Proc 2003; 78: 421–430
- Tsakiris D A, Marbet G A, Tichelli A, Gratwohl, Speck B. Activation of endothelium-dependent hemostatic factors following bone marrow transplantation. Schweiz Med Wochenschr 1995; 125: 416–419
- Lunn R A, Sumar N, Bansal A S, Treleaven J. Cytokine profiles in stem cell transplantation: Possible use as a predictor of graft-versus-host disease. Hematology 2005; 10: 107–114
- Min C-K, Kim S Y, Lee M J, Eom K S, Kim Y J, Kim H J, et al. Vascular endothelial growth factor (VEGF) is associated with reduced severity of acute graft-versus-host disease and nonrelapse mortality after allogeneic stem cell transplantation. Bone Marrow Transplant 2006; 38: 149–156